<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>obesity — GZERO Media</title>
<link>https://www.gzeromedia.com/tag/obesity</link>
<description>The latest news and analysis from GZERO Media.</description>
<language>en</language>
<copyright>© GZERO Media</copyright>
<atom:link href="https://www.gzeromedia.com/feeds/tag/obesity.xml" rel="self" type="application/rss+xml" />
<lastBuildDate>Mon, 02 Nov 2026 18:42:20 +0000</lastBuildDate>
<item>
<title>The GLP-1 world</title>
<link>https://www.gzeromedia.com/news/graphic-truth/the-glp-1-world</link>
<guid isPermaLink="false">cmvrggxf7mz3307lqhmgwgvml</guid>
<pubDate>Mon, 10 Aug 2026 15:38:42 +0000</pubDate>
<dc:creator>Natalie Johnson, Eileen Zhang</dc:creator>
<category>weight loss</category>
<category>healthcare</category>
<category>world health organization</category>
<category>obesity</category>
<category>glp-1</category>
<category>graphic truth</category>
<description>Roughly 11% of American adults now say they are taking GLP-1s for weight loss, up from just 3% in 2024.</description>
<media:content url="https://us-west-2.graphassets.com/cmrcgvnh6064507n8hhitfmjj/cmvrdrmobdyca07myq6o4qecj" type="image/png" medium="image" width="1200" height="900">
<media:credit>Eileen Zhang</media:credit>
</media:content>
<media:thumbnail url="https://us-west-2.graphassets.com/cmrcgvnh6064507n8hhitfmjj/cmvrdrmobdyca07myq6o4qecj" />
<content:encoded><![CDATA[<p>Forget the G-zero world for a minute. Today, we’re looking at the GLP-1 world.</p><p>GLP-1 medications, which regulate blood sugar, slow digestion, and, most famously, suppress appetite, are booming. You may know them by their popular brand names: Ozempic, Mounjaro, and Zepbound.</p><p>Originally developed to treat Type 2 diabetes, the drugs became a phenomenon over the past five years as regulators like the US Food and Drug Administration approved them for weight loss. Now, they are reshaping how obesity is treated and creating an enormous new market, expected to <a rel="noopener noreferrer" target="_blank" href="https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs"><u>reach</u></a> $200 billion by 2030.</p><p>But the GLP-1 boom is far from evenly distributed. In the United States, 74% of adults have heard of the drugs, compared with just 9% in Colombia, as our Graphic Truth shows. Awareness is also high in Canada, at 70%, and across parts of Europe and Australia.</p><p>The US is where uptake has been most dramatic. Roughly 11% of American adults now <a rel="noopener noreferrer" target="_blank" href="https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx"><u>say</u></a> they are taking GLP-1s for weight loss, up from just 3% in 2024. Research suggests the drugs are contributing to declining obesity rates, and their reach is expected to grow considerably: Around 10 million Americans currently take the drugs, a figure that is projected to hit 25 million by 2030.</p><p>But GLP-1s remain expensive, especially for people without insurance coverage in the US, costing around <a rel="noopener noreferrer" target="_blank" href="https://www.theguardian.com/us-news/2026/apr/14/states-medicaid-coverage-glp-1"><u>$400 a month</u></a> for some brands. In one <a rel="noopener noreferrer" target="_blank" href="https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/"><u>survey</u></a> of Americans taking the medications, over half said they struggle to afford them either with or without insurance. As demand has surged, President <strong>Donald Trump</strong> announced a deal last year that would <a rel="noopener noreferrer" target="_blank" href="https://www.nytimes.com/2025/11/06/health/obesity-drug-prices-trump.html"><u>lower</u></a> the cost of major GLP-1 drugs.</p><p>Canada, where roughly 8% of the population are currently taking GLP-1s, is following a path similar to that of the US. In May, Canada became the first G7 country to approve a generic version of the medication, potentially opening the door to cheaper treatment.</p><p>GLP-1 use is far lower in Europe. According to ING, it accounts for around 2% of adults across the EU and the UK combined. That divide isn’t simply about demand. It also reflects differences in healthcare systems and attitudes toward treating obesity as a chronic disease rather than a matter of willpower.</p><p>In other words, the GLP-1 world is booming, but its global footprint remains starkly uneven.</p>]]></content:encoded>
</item>
<item>
<title>Hard Numbers: Ukraine adds fresh twist to fundraising, USDA employees reinstated, Alarming world obesity forecast, Loads of Americans want UK citizenship, China bumps up defense budget</title>
<link>https://www.gzeromedia.com/news/hard-numbers/hard-numbers-ukraine-adds-fresh-twist-to-fundraising-usda-employees-reinstated-alarming-world-obesity-forecast-loads-of-americans-want-uk-citizenship-china-bumps-up-defense-budget</link>
<guid isPermaLink="false">cmvrg3drhkyam07myd6udapb2</guid>
<pubDate>Wed, 05 Mar 2025 20:40:17 +0000</pubDate>
<dc:creator>Billy  Pickett</dc:creator>
<category>obesity</category>
<category>united states</category>
<category>canada</category>
<category>donald trump</category>
<category>ukrainian fundraising</category>
<category>russia</category>
<category>ukraine</category>
<category>china</category>
<category>defense spending</category>
<category>volodymyr zelensky</category>
<category>Hard Numbers</category>
<description>100: When life gives you lemons, why not sell lemon t-shirts?</description>
<media:content url="https://us-west-2.graphassets.com/cmrcgvnh6064507n8hhitfmjj/cmvrd8gwte0gf07lqjxf6lshr" type="image/jpeg" medium="image" width="1179" height="662">
<media:credit>Joshua Sukoff/Medill News Service/Sipa USA via Reuters</media:credit>
<media:text>President Donald Trump is seen here welcoming Ukrainian President Volodymyr Zelensky to the White House last Friday.</media:text>
</media:content>
<media:thumbnail url="https://us-west-2.graphassets.com/cmrcgvnh6064507n8hhitfmjj/cmvrd8gwte0gf07lqjxf6lshr" />
<content:encoded><![CDATA[<p><strong>100</strong>: When life gives you lemons, why not sell lemon t-shirts? United24, a fundraising platform led by the Ukrainian government, is raffling off <a target="_blank" href="https://donorbox.org/help-ukraine-finish-the-war?utm_source=website&amp;utm_medium=fundraising&amp;utm_campaign=raffle-quote"><u>shirts</u></a> featuring a quote from <strong>Volodymyr Zelensky’s</strong> contentious Oval Office meeting. A tee with the phrase, “I’ll wear the costume when this war is over,” will be sent to 100 lucky donors, harkening back to <strong>Donald Trump’s</strong> jabs at Zelensky’s refusal to wear a suit to the White House (he wore his usual war attire in solidarity with Ukrainian soldiers).</p><p><strong>6,000</strong>: The independent United States Merit Systems Protection Board, a workers' rights watchdog, is<a rel="noopener noreferrer" target="_blank" href="https://www.cnn.com/2025/03/05/politics/usda-employees-fired-reinstatement"> <u>reinstating</u></a> nearly 6,000 recently hired US Department of Agriculture employees who were terminated en masse by the Trump administration. The board directed USDA to <a rel="noopener noreferrer" target="_blank" href="https://www.npr.org/2025/03/05/nx-s1-5318687/usda-fired-federal-employees-probationary-osc-mspb"><u>reinstate</u></a> the employees for 45 days pending an investigation into whether the government violated civil service laws by dismissing them. Meanwhile, the Trump Administration is now <a rel="noopener noreferrer" target="_blank" href="https://apnews.com/article/veterans-affairs-cuts-doge-musk-trump-f587a6bc3db6a460e9c357592e165712?user_email=05730c92b94f641e215b3b9c7bcd044052530d1561200a62e4e5201afab6c930&amp;utm_medium=Afternoon_Wire&amp;utm_source=Sailthru_AP&amp;utm_campaign=AfternoonWire_March5_2025&amp;utm_term=Afternoon%20Wire"><u>planning to slash</u></a> 80,000 employees from the Veterans Affairs Department to bring staffing there back to 2019 levels.</p><p><strong>3,800,000,000:&nbsp;</strong>According to a new study published in The Lancet, <a rel="noopener noreferrer" target="_blank" href="https://qz.com/obesity-study-2050-wegovy-glp-1s-ozempic-1851767614">a medical journal, <u>more than half</u></a> of the global population – 3.8 billion people – is expected to be overweight or obese by 2050 if present trends continue. A global increase in diabetes, cardiovascular disease, cancer, and other obesity-related ailments is expected in conjunction with obesity rates. Experts don’t expect GLP-1 medications like Ozempic and Wegovy to curb the epidemic due to their high costs and inaccessibility.</p><p><strong>40:&nbsp;</strong>President <strong>Donald Trump’s</strong> reelection and UK tax policy changes helped contribute to a record number of Americans trying to move across the pond last year. The UK Home Office <a rel="noopener noreferrer" target="_blank" href="https://www.ft.com/content/e20a2ea0-0fa0-4b6c-a487-05030f4a4c93"><u>reported</u></a> a 26% increase in American applications for British citizenship in 2024, spiking 40% during the last quarter.</p><p><strong>7.2</strong>: On Wednesday, China announced a defense budget <a rel="noopener noreferrer" target="_blank" href="https://apnews.com/article/china-defense-budget-taiwan-4ac7cbdc7d5b889732cd55916ff7eb36"><u>increase</u></a> of 7.2%, matching the same percentage boost as in 2024. With the second largest military expenditure in the world, any increase is significant. But the change doesn’t quite hit the double-digit increases of years past, a reflection of China’s sluggish economy.</p>]]></content:encoded>
</item>
<item>
<title>Graphic Truth: Obesity on the rise</title>
<link>https://www.gzeromedia.com/gzero-north/graphic-truth-obesity-on-the-rise</link>
<guid isPermaLink="false">cmvrfys89kjlq07my8bxgeq2j</guid>
<pubDate>Thu, 21 Nov 2024 16:30:22 +0000</pubDate>
<dc:creator>Riley Callanan</dc:creator>
<category>obesity</category>
<category>GZERO North</category>
<description>Obesity rates have risen strikingly since the 1990s in the US, according to a new study from The Lancet, with nearly three-quarters of the country overweight or obese — and more than 50% considered obese or severely obese.</description>
<media:content url="https://us-west-2.graphassets.com/cmrcgvnh6064507n8hhitfmjj/cmvrd16wsdb9w07lqyc4v29c4" type="image/png" medium="image" width="2500" height="2358">
<media:credit>Paige Fusco</media:credit>
<media:text>Obesity and Ozempic use in the US and Canada</media:text>
</media:content>
<media:thumbnail url="https://us-west-2.graphassets.com/cmrcgvnh6064507n8hhitfmjj/cmvrd16wsdb9w07lqyc4v29c4" />
<content:encoded><![CDATA[<p>Obesity rates have risen strikingly since the 1990s in the US, according to a new<a rel="noopener noreferrer" target="_blank" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01548-4/fulltext"> <u>study</u></a> from The Lancet, with nearly three-quarters of the country overweight or obese — and more than 50% considered obese or severely obese. Obesity has also been on the rise in Canada, with 30% of adults considered obese in 2023.</p><p>Amidst skyrocketing obesity, usage of Ozempic — a drug that aids with weight loss by mimicking the “fullness” hormone in the brain and curbing appetite — has also been increasing, with prescriptions rising by <a rel="noopener noreferrer" target="_blank" href="https://www.cnbc.com/2023/09/27/ozempic-wegovy-drug-prescriptions-hit-9-million.html"><u>300%</u></a> in the US between 2020-2022. As of 2023, 12% of adults in Canada use the drug, compared to 10% in the US. While usage levels are relatively similar in both countries, prices are drastically different, with the weight loss drug costing over $600 more per month in the US.</p><p>This has led many Americans to cross the<a rel="noopener noreferrer" target="_blank" href="https://www.businessinsider.com/americans-buying-cheaper-ozempic-semaglutide-canada-mexico-pharmacy-2023-3"> <u>northern</u></a> border to obtain the drug. And numbers could grow depending on policies put in place by <strong>Donald Trump’</strong>s nominee for Health and Human Services, <strong>Robert F Kennedy Jr.</strong>, who has been highly critical of Ozempic as a treatment for obesity and diabetes.</p>]]></content:encoded>
</item>
</channel>
</rss>